The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease

Ursula C Brewster1, Mark A Perazella

  • 1Section of Nephrology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520-8029, USA.

Insights

The renin-angiotensin-aldosterone system contributes to kidney disease progression. Inhibiting this system, using agents like ACE inhibitors, can slow chronic kidney disease advancement in proteinuric conditions.

Area of Science:

  • Nephrology
  • Endocrinology
  • Cardiovascular Physiology

Background:

  • The renin-angiotensin-aldosterone system (RAAS) is crucial for regulating blood pressure, fluid balance, and kidney growth.
  • Overactivation of the RAAS contributes significantly to the pathophysiology of various kidney diseases.
  • RAAS overactivity leads to hypertension and direct cellular damage within the kidney.

Purpose of the Study:

  • To provide an overview of the renin-angiotensin system.
  • To review the role of RAAS in kidney disease.
  • To examine the effects of RAAS inhibition in preclinical models and clinical studies.

Main Methods:

  • Review of existing literature on the renin-angiotensin-aldosterone system and kidney disease.
  • Analysis of experimental animal models demonstrating the renal effects of RAAS inhibition.
  • Review of clinical studies evaluating RAAS inhibitors in diabetic and nondiabetic nephropathies.

Main Results:

  • Activated RAAS promotes systemic and glomerular hypertension, causing hemodynamic injury.
  • Angiotensin II and aldosterone exert direct profibrotic and proinflammatory effects on the kidney.
  • Inhibitors of the RAAS cascade have shown potential in reducing chronic kidney disease progression.

Conclusions:

  • Understanding the RAAS is key to managing kidney disease.
  • Pharmacologic inhibition of the RAAS, including ACE inhibitors, ARBs, and aldosterone antagonists, is a viable strategy to mitigate kidney damage.
  • RAAS inhibitors demonstrate efficacy in slowing the progression of proteinuric kidney diseases.

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Introduction to Urinary System01:13

Introduction to Urinary System

The urinary system consists of two kidneys, two ureters, the urinary bladder, and the urethra.
The kidneys are bean-shaped organs located in the retroperitoneal space, on either side of the vertebral column, between the T12 and L3 vertebrae. They are partially protected by the rib cage and surrounded by perirenal fat, which provides cushioning. They are responsible for urine formation and play critical roles in regulating blood pressure, electrolyte levels, and hormone production. The ureters...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...